Funding round
NewLimit Growth
Reported as "Growth Equity"
NewLimit, which works in epigenetic reprogramming medicine development in South San Francisco, raised $45M in a Growth round announced on 20 Oct 2025, led by Eli Lilly and Company, at a $1.62B post-money valuation. 13 firms took part. It is NewLimit's third venture round on record; the one before was a Series B in May 2025.
$45M
Amount raised
$1.62B
Post-money valuation
$1.57B pre-money
13
Investors
1 lead
2.8%
Stake sold
new money over the post-money
Valuation
What this round says about the price
This round priced NewLimit at $1.62B after the new money. The $45M bought investors about 2.8% of the company. It came 5 months after NewLimit's Series B. It is 6.9% of the $650M NewLimit has raised in the venture rounds on record. NewLimit raised again 8 months later: a Series C round of $435M in Jun 2026, at $3.10B post-money.
NewLimit's funding rounds
NewLimit has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
Eli Lilly and Company led the round with 12 other firms.
Lead investor
- Eli Lilly and Company new investor
Also in the round
- Duke Management Co new investor
- Section 32 new investor
- Abstract new investor
- Kleiner Perkins backs 285 venture-backed companies new investor
- backs 24 venture-backed companies new investor
- backs 55 venture-backed companies new investor
- backs 77 venture-backed companies new investor
- Lilly Ventures
- GreatThings new investor
- backs 4 venture-backed companies new investor
- backs 5 venture-backed companies new investor
- NFDG new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
38 Growth rounds in Biotechnology within a year either side disclosed an amount; the median was $50M, and this round was close to the median. The closest in time, other companies' Growth rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 29 Oct 2025 | $60M | not disclosed | not named |
| Biotechnology | 28 Oct 2025 | $50M | not disclosed | Flagship Pioneering |
| Biotechnology | 14 Oct 2025 | $50M | not disclosed | The Column Group |
| Biotechnology | 1 Oct 2025 | undisclosed | not disclosed | not named |
| Biotechnology | 18 Nov 2025 | $112M | not disclosed | not named |
| Biotechnology | 22 Sep 2025 | $53M | not disclosed | Gilead Sciences |
| Biotechnology | 17 Dec 2025 | $100M | not disclosed | not named |
| Biotechnology | 1 Aug 2025 | $50M | not disclosed | not named |
Sources
Where this comes from
Reported by 6 sources.
Questions
Frequently asked
How much did NewLimit raise in its Growth round?
NewLimit raised $45M in its Growth round, announced in Oct 2025.
Who led NewLimit's Growth round?
Eli Lilly and Company led it, with Duke Management Co, Section 32, Abstract, Kleiner Perkins and Dimension and 7 more.
What was NewLimit's valuation at the Growth round?
$1.62B post-money ($1.57B pre-money).
How does it compare with other Growth rounds in Biotechnology?
38 Growth rounds in Biotechnology within a year either side disclosed an amount; the median was $50M, and this round was close to the median.
Did NewLimit raise again after this round?
Yes: a Series C round in Jun 2026 of $435M at $3.10B post-money.